Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov;40(12):2822-31.
doi: 10.1038/npp.2015.132. Epub 2015 May 8.

Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine

Affiliations
Randomized Controlled Trial

Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine

Kyung-Heup Ahn et al. Neuropsychopharmacology. 2015 Nov.

Abstract

Some schizophrenia patients are more sensitive to amphetamine (AMPH)-induced exacerbations in psychosis-an effect that correlates with higher striatal dopamine release. This enhanced vulnerability may be related to gamma-aminobutyric acid (GABA) deficits observed in schizophrenia. We hypothesized that a pharmacologically induced GABA deficit would create vulnerability to the psychotomimetic effects to the 'subthreshold' dose of AMPH in healthy subjects, which by itself would not induce clinically significant increase in positive symptoms. To test this hypothesis, a GABA deficit was induced by intravenous infusion of iomazenil (IOM; 3.7 μg/kg), an antagonist and partial inverse agonist of benzodiazepine receptor. A subthreshold dose of AMPH (0.1 mg/kg) was administered by intravenous infusion. Healthy subjects received placebo IOM followed by placebo AMPH, active IOM followed by placebo AMPH, placebo IOM followed by active AMPH, and active IOM followed by active AMPH in a randomized, double-blind crossover design over 4 test days. Twelve healthy subjects who had a subclinical response to active AMPH alone were included in the analysis. Psychotomimetic effects (Positive and Negative Syndrome Scale (PANSS)), perceptual alterations (Clinician Administered Dissociative Symptoms Scale (CADSS)), and subjective effects (visual analog scale) were captured before and after the administration of drugs. IOM significantly augmented AMPH-induced peak changes in PANSS positive symptom subscale and both subjective and objective CADSS scores. There were no pharmacokinetic interactions. In conclusion, GABA deficits increased vulnerability to amphetamine-induced psychosis-relevant effects in healthy subjects, suggesting that pre-existing GABA deficits may explain why a subgroup of schizophrenia patients are vulnerable to AMPH.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of amphetamine and iomazenil on Positive and Negative Syndrome Scale (PANSS)-positive symptoms subscale. □ amphetamine+iomazenil, ♦ amphetamine+placebo, ▴ iomazenil+placebo, and ○ placebo+placebo.

Similar articles

Cited by

References

    1. Abel KM, Allin MP, Hemsley DR, Geyer MA (2003). Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44: 729–737. - PubMed
    1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761–767. - PubMed
    1. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65: 1091–1093. - PubMed
    1. Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A et al (2002). Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl) 162: 55–62. - PubMed
    1. Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC (2011). Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 36: 677–683. - PMC - PubMed

Publication types

MeSH terms